Vensobafusp Alfa Biosimilar – Anti-CPAMD4 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA1996; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Vensobafusp Alfa Biosimilar, also known as Anti-CPAMD4 fusion protein, is a novel therapeutic antibody that has shown promising results in the treatment of various diseases. In this article, we will discuss the structure, activity, and potential applications of this biosimilar in detail.
Vensobafusp Alfa Biosimilar is a fusion protein composed of two distinct parts: an antibody and a therapeutic target. The antibody component is a monoclonal antibody that specifically binds to the CPAMD4 protein, while the therapeutic target is a small molecule that inhibits the activity of CPAMD4.
The antibody component of Vensobafusp Alfa Biosimilar is derived from a humanized monoclonal antibody, which means that it has been modified to reduce its immunogenicity and increase its affinity for the target protein. This antibody has a high specificity for CPAMD4, which is a protein involved in the regulation of cell growth and survival. The therapeutic target, on the other hand, is a small molecule inhibitor that binds to CPAMD4 and blocks its activity.
The main activity of Vensobafusp Alfa Biosimilar is the inhibition of CPAMD4, which plays a crucial role in the development and progression of various diseases. CPAMD4 is overexpressed in many types of cancer, including breast, lung, and prostate cancer, and has been linked to tumor growth, invasion, and metastasis. By targeting CPAMD4, Vensobafusp Alfa Biosimilar can potentially stop or slow down the progression of these cancers.
Furthermore, CPAMD4 has also been implicated in other diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. In these conditions, CPAMD4 promotes the growth of abnormal blood vessels in the eye, leading to vision loss. By inhibiting CPAMD4, Vensobafusp Alfa Biosimilar may be able to prevent the formation of these abnormal blood vessels and preserve vision.
Vensobafusp Alfa Biosimilar has the potential to be used in the treatment of various diseases, particularly in the field of oncology and ophthalmology. In oncology, this biosimilar can be used as a targeted therapy for cancers that overexpress CPAMD4. It can be used alone or in combination with other treatments, such as chemotherapy, to improve efficacy and reduce side effects.
In ophthalmology, Vensobafusp Alfa Biosimilar can be used to treat AMD and diabetic retinopathy. These conditions are major causes of vision loss and currently have limited treatment options. By inhibiting CPAMD4, this biosimilar may provide a new and effective treatment option for these diseases.
Moreover, Vensobafusp Alfa Biosimilar can also be used as a research tool in the study of CPAMD4 and its role in various diseases. Its high specificity and potency make it a valuable tool for understanding the function of CPAMD4 and its potential as a therapeutic target.
In summary, Vensobafusp Alfa Biosimilar, also known as Anti-CPAMD4 fusion protein, is a novel therapeutic antibody with the potential to treat various diseases, particularly in the fields of oncology and ophthalmology. Its unique structure, targeting CPAMD4, makes it a promising candidate for the treatment of cancers and eye diseases. Furthermore, it can also serve as a valuable research tool in the study of CPAMD4 and its role in disease development and progression. With further research and development, Vensobafusp Alfa Biosimilar may become an important addition to the arsenal of treatments for these diseases.
ProteoGenix catalogue number PX-TA1996. For research use only.
Target: Vensobafusp Alfa Biosimilar – Anti-CPAMD4 fusion protein – Research Grade; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Vensobafusp Alfa Biosimilar – Anti-CPAMD4 fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
